Evidence map›Paper›PMID 29629690›Full record

ArticleSICOT-J2018

Osteosarcoma: a comprehensive review.

Amirhossein Misaghi, Amanda Goldin, Moayd Awad, Anna A Kulidjian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SICOT-J, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 287 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
287citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

287 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Health-related quality of life in patients with extremity bone sarcoma after surgical treatment: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Anticancer Activity of Green Synthesized ZnO Nanoparticles fromNanomaterials (Basel, Switzerland) · 2026
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

227 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amirhossein MisaghiDepartment of Orthopaedic Surgery, University of California San Diego, San Diego, CA, USA.
Amanda GoldinDepartment of Orthopaedic Surgery, University of California San Diego, San Diego, CA, USA.
Moayd AwadDepartment of Orthopaedic Surgery, University of California San Diego, San Diego, CA, USA - School of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
Anna A KulidjianDepartment of Orthopaedic Surgery, University of California San Diego, San Diego, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is a relatively rare tumor of bone with a worldwide incidence of 3.4 cases per million people per year. For most of the twentieth century, five-year survival rates for classic OS were very low. In the 1970s, the introduction of adjuvant chemotherapy in the treatment of OS increased survival rates dramatically. The current article reviews the various types of OS and analyzes the clinical and histological features. We also examine historical and current literature to present a succinct review of methods for diagnosis and staging, as well as treatment, and we also discuss some of the future directions of treatment.

Identifiers

PMID29629690
PMCPMC5890448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.